Pfizer
Bharat Damle, PhD has extensive work experience in the pharmaceutical industry, primarily at Pfizer Pharmaceuticals. Bharat joined Pfizer in 2011 as a Senior Director and was later promoted to Vice President, Clinical Pharmacology in 2022. Prior to joining Pfizer, they worked at Bristol-Myers Squibb as a Senior Research Investigator from 2000 to 2004 and as a Research Investigator from 1995 to 2000. Bharat's career in the industry began at Prin. K. M.K. College of Pharmacy where they studied as a student from 1984 to 1988.
From 1990 to 1995, Bharat Damle pursued their education at the University of Louisiana Monroe. No specific degree or field of study has been mentioned.
Pfizer
605 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.